BioSpace News Archive

Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to lead and provide full service clinical trial support of the Adalimumab COVID Therapeutic Trial.

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company’s proprietary NK cell engager (TriKE™) technology platform today announced the appointment of Michael Breen and Rajesh Shrotriya MD to the Company’s Board of Directors (the “Board”), effective immediat

Jan. 19, 2021 14:00 UTC LOS ANGELES--( BUSINESS WIRE )-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company on January 21, 2021 at the virtual B. Riley Oncology Investor Conference. A replay of the presentation will be available for 30 days beginning at approximately 1:30 p.m. PST on January 21, 2021 on the Company’s website

- $2 million Phase II SBIR grant awarded to advance image-guided alpha-particle therapy for metastatic melanoma and radioisotope production technologies - Second year of a $2 million Phase II SBIR funding to begin a Phase 1 clinical imaging trial of complementary Pb-203 and Ga-68 diagnostics for metastatic melanoma - $2 million Phase II Small Business Innovation Research (SBIR) grant awarded to fund development activities and advance preclinical studies of VMT-

CarepathRx, a leader in pharmacy and medication management solutions, announced the formation of a comprehensive partnership to fully integrate the pharmacy operations of Knox Community Hospital.

RSIP Vision, a leading innovator in medical imaging through advanced AI and computer vision solutions, today announces a general purpose, AI-based segmentation and measurement tool for detecting objects of interest and their boundaries quickly and automatically, making surgical and diagnostic measurements easier and more accurate for better treatment decisions.

Immunovia AB, (“Immunovia”) announces today that Patrik Dahlen , CEO of Immunovia, has purchased 250,000 warrants of the 2020/2024 scheme for approximately 400 KSEK. His total holding now amounts to 45,000 shares and 250,000 warrants in Immunovia. The warrants have a subscription price per share of SEK 455 . Other management team

Secarnas partner Lipigon has selected an LNAplus TM ASO candidate targeting ANGPTL4, called Lipisense, which has shown unique efficacy in reducing lipid triglycerides in experimental disease models and is now entering pre-clinical safety development High levels of plasma lipids triglycerides are associated with a plethora of lipid-related diseases with yet unmet clinical treatment needs

n, a subsidiary of Modern Mobility Aids, Inc., announced progress on many steps taken to refocus its business model of providing virtual healthcare services.

Training in healthcare has transformed in response to challenges caused by the Covid-19 pandemic.